Cardiovascular outcomes associated with SGLT-2 inhibitors versus other glucose-lowering drugs in patients with type 2 diabetes: A real-world systematic review and meta-analysis

BACKGROUND AND AIMS: Glucose lowering agents that reduce the risk of major adverse cardiovascular events (MACE) would be considered a major advance. The reduction of cardiovascular risk by sodium-glucose cotransporter 2 inhibitors (SGLT-2i) has been confirmed by some large-scale randomized controlle...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Chun-xing, Liang, Shuo, Gao, Lingyan, Liu, Hua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7895346/
https://www.ncbi.nlm.nih.gov/pubmed/33606705
http://dx.doi.org/10.1371/journal.pone.0244689

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7895346/
https://www.ncbi.nlm.nih.gov/pubmed/33606705
http://dx.doi.org/10.1371/journal.pone.0244689

Ejemplares similares